Cipla announced that it filed two generic respiratory drug applications with the US FDA in the last quarter, including a generic version of Symbicort and one other undisclosed inhalation product.

Objective: To compare the efficacy and tolerability of a salmeterol/fluticasone propionate (FP ... alternative to increasing the dose of inhaled corticosteroids, without the need for an additional ...

Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate ... patients to double the dose of their inhaled corticosteroid medication for a ...